Oliver Lagore Vanvalin Investment Group’s GSK GSK Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$19.7K	Buy	+508	New	+$19.4K	0.01%	340
2024 Q4	$17.5K	Sell	518 -53	-9%	-$1.91K	﹤0.01%	381
2024 Q3	$23.3K	Sell	571 -85	-13%	-$3.48K	0.01%	330
2024 Q2	$25.3K	Sell	656 -51	-7%	-$2.15K	0.01%	311
2024 Q1	$30.3K	Sell	707 -5	-0.7%	-$206	0.01%	294
2023 Q4	$26.4K	Buy	712 +45	+7%	+$1.61K	0.01%	286
2023 Q3	$24.2K	Buy	667 +89	+15%	+$3.16K	0.01%	326
2023 Q2	$20.6K	Hold	578	–	–	0.01%	368
2023 Q1	$20.6K	Buy	578 +1	+0.2%	+$35	0.01%	281
2022 Q4	$20.3K	Buy	577 +324	+128%	+$10.8K	0.01%	273
2022 Q3	$7K	Buy	253 +79	+45%	+$2.99K	﹤0.01%	386
2022 Q2	$9K	Buy	174 +14	+9%	+$773	0.01%	347
2022 Q1	$9K	Buy	+160	New	+$8.69K	0.01%	345

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's GSK Position: Q2 2025 in Review

Oliver Lagore Vanvalin Investment Group opened a new position in GSK (GSK) in Q2 2025: 508 shares worth $19.7K. The stake represents 0.01% of the portfolio and ranks #340 among its holdings. This is a return to the name: Oliver Lagore Vanvalin Investment Group previously reported a position in GSK as recently as Q4 2024.

Oliver Lagore Vanvalin Investment Group first reported a position in GSK in Q1 2022 and has held it in 13 quarters since. The position peaked at $30.3K in Q1 2024. 890 funds tracked by Wall St. Rank hold GSK as of Q2 2025.

Oliver Lagore Vanvalin Investment Group held 508 shares of GSK worth $19.7K as of Q2 2025.
GSK was a new Oliver Lagore Vanvalin Investment Group position in Q2 2025.
GSK made up 0.01% of Oliver Lagore Vanvalin Investment Group's portfolio in Q2 2025, its #340 holding.
Oliver Lagore Vanvalin Investment Group first reported a position in GSK in Q1 2022 and has held it in 13 quarters since.
Oliver Lagore Vanvalin Investment Group's GSK position peaked at $30.3K in Q1 2024.
890 funds tracked by Wall St. Rank held GSK as of Q2 2025.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q2 2025, filed 10 Jul 2025.